-
1
-
-
0029947568
-
Enhancement of antitumor immunity by CTLA-4 blockade
-
D. R. Leach, M. F. Krummel, J. P. Allison, Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736 (1996).
-
(1996)
Science
, vol.271
, pp. 1734-1736
-
-
Leach, D.R.1
Krummel, M.F.2
Allison, J.P.3
-
2
-
-
84858766182
-
The blockade of immune checkpoints in cancer immunotherapy
-
D. M. Pardoll, The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
-
(2012)
Nat. Rev. Cancer
, vol.12
, pp. 252-264
-
-
Pardoll, D.M.1
-
3
-
-
84928062583
-
Immune checkpoint blockade: A common denominator approach to cancer therapy
-
S. L. Topalian, C. G. Drake, D. M. Pardoll, Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 27, 450-461 (2015).
-
(2015)
Cancer Cell
, vol.27
, pp. 450-461
-
-
Topalian, S.L.1
Drake, C.G.2
Pardoll, D.M.3
-
4
-
-
84938350452
-
Combination cancer immunotherapy and new immunomodulatory targets
-
K. M. Mahoney, P. D. Rennert, G. J. Freeman, Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14, 561-584 (2015).
-
(2015)
Nat. Rev. Drug Discov.
, vol.14
, pp. 561-584
-
-
Mahoney, K.M.1
Rennert, P.D.2
Freeman, G.J.3
-
6
-
-
79953151458
-
Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion
-
R. D. Schreiber, L. J. Old, M. J. Smyth, Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331, 1565-1570 (2011).
-
(2011)
Science
, vol.331
, pp. 1565-1570
-
-
Schreiber, R.D.1
Old, L.J.2
Smyth, M.J.3
-
7
-
-
84880706152
-
Oncology meets immunology: The cancer-immunity cycle
-
D. S. Chen, I. Mellman, Oncology meets immunology: The cancer-immunity cycle. Immunity 39, 1-10 (2013).
-
(2013)
Immunity
, vol.39
, pp. 1-10
-
-
Chen, D.S.1
Mellman, I.2
-
8
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith, D. F. McDermott, J. D. Powderly, R. D. Carvajal, J. A. Sosman, M. B. Atkins, P. D. Leming, D. R. Spigel, S. J. Antonia, L. Horn, C. G. Drake, D. M. Pardoll, L. Chen, W. H. Sharfman, R. A. Anders, J. M. Taube, T. L. McMiller, H. Xu, A. J. Korman, M. Jure-Kunkel, S. Agrawal, D. McDonald, G. D. Kollia, A. Gupta, J. M. Wigginton, M. Sznol, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
Gettinger, S.N.4
Smith, D.C.5
McDermott, D.F.6
Powderly, J.D.7
Carvajal, R.D.8
Sosman, J.A.9
Atkins, M.B.10
Leming, P.D.11
Spigel, D.R.12
Antonia, S.J.13
Horn, L.14
Drake, C.G.15
Pardoll, D.M.16
Chen, L.17
Sharfman, W.H.18
Anders, R.A.19
Taube, J.M.20
McMiller, T.L.21
Xu, H.22
Korman, A.J.23
Jure-Kunkel, M.24
Agrawal, S.25
McDonald, D.26
Kollia, G.D.27
Gupta, A.28
Wigginton, J.M.29
Sznol, M.30
more..
-
9
-
-
84929481480
-
Pembrolizumab for the treatment of non-small-cell lung cancer
-
E. B. Garon, N. A. Rizvi, R. Hui, N. Leighl, A. S. Balmanoukian, J. P. Eder, A. Patnaik, C. Aggarwal, M. Gubens, L. Horn, E. Carcereny, M.-J. Ahn, E. Felip, J.-S. Lee, M. D. Hellmann, O. Hamid, J. W. Goldman, J.-C. Soria, M. Dolled-Filhart, R. Z. Rutledge, J. Zhang, J. K. Lunceford, R. Rangwala, G. M. Lubiniecki, C. Roach, K. Emancipator, L. Gandhi; KEYNOTE-001 Investigators, Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
-
(2015)
N. Engl. J. Med.
, vol.372
, pp. 2018-2028
-
-
Garon, E.B.1
Rizvi, N.A.2
Hui, R.3
Leighl, N.4
Balmanoukian, A.S.5
Eder, J.P.6
Patnaik, A.7
Aggarwal, C.8
Gubens, M.9
Horn, L.10
Carcereny, E.11
Ahn, M.-J.12
Felip, E.13
Lee, J.-S.14
Hellmann, M.D.15
Hamid, O.16
Goldman, J.W.17
Soria, J.-C.18
Dolled-Filhart, M.19
Rutledge, R.Z.20
Zhang, J.21
Lunceford, J.K.22
Rangwala, R.23
Lubiniecki, G.M.24
Roach, C.25
Emancipator, K.26
Gandhi, L.27
more..
-
10
-
-
84920956732
-
PD-1 blockade induces responses by inhibiting adaptive immune resistance
-
P. C. Tumeh, C. L. Harview, J. H. Yearley, I. P. Shintaku, E. J. M. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, A. N. West, M. Carmona, C. Kivork, E. Seja, G. Cherry, A. J. Gutierrez, T. R. Grogan, C. Mateus, G. Tomasic, J. A. Glaspy, R. O. Emerson, H. Robins, R. H. Pierce, D. A. Elashoff, C. Robert, A. Ribas, PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
-
(2014)
Nature
, vol.515
, pp. 568-571
-
-
Tumeh, P.C.1
Harview, C.L.2
Yearley, J.H.3
Shintaku, I.P.4
Taylor, E.J.M.5
Robert, L.6
Chmielowski, B.7
Spasic, M.8
Henry, G.9
Ciobanu, V.10
West, A.N.11
Carmona, M.12
Kivork, C.13
Seja, E.14
Cherry, G.15
Gutierrez, A.J.16
Grogan, T.R.17
Mateus, C.18
Tomasic, G.19
Glaspy, J.A.20
Emerson, R.O.21
Robins, H.22
Pierce, R.H.23
Elashoff, D.A.24
Robert, C.25
Ribas, A.26
more..
-
11
-
-
84928761118
-
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
-
N. A. Rizvi, M. D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, J. J. Havel, W. Lee, J. Yuan, P. Wong, T. S. Ho, M. L. Miller, N. Rekhtman, A. L. Moreira, F. Ibrahim, C. Bruggeman, B. Gasmi, R. Zappasodi, Y. Maeda, C. Sander, E. B. Garon, T. Merghoub, J. D. Wolchok, T. N. Schumacher, T. A. Chan, Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
-
(2015)
Science
, vol.348
, pp. 124-128
-
-
Rizvi, N.A.1
Hellmann, M.D.2
Snyder, A.3
Kvistborg, P.4
Makarov, V.5
Havel, J.J.6
Lee, W.7
Yuan, J.8
Wong, P.9
Ho, T.S.10
Miller, M.L.11
Rekhtman, N.12
Moreira, A.L.13
Ibrahim, F.14
Bruggeman, C.15
Gasmi, B.16
Zappasodi, R.17
Maeda, Y.18
Sander, C.19
Garon, E.B.20
Merghoub, T.21
Wolchok, J.D.22
Schumacher, T.N.23
Chan, T.A.24
more..
-
12
-
-
84928770388
-
Neoantigens in cancer immunotherapy
-
T. N. Schumacher, R. D. Schreiber, Neoantigens in cancer immunotherapy. Science 348, 69-74 (2015).
-
(2015)
Science
, vol.348
, pp. 69-74
-
-
Schumacher, T.N.1
Schreiber, R.D.2
-
13
-
-
84920962202
-
Molecular and genetic properties of tumors associated with local immune cytolytic activity
-
M. S. Rooney, S. A. Shukla, C. J. Wu, G. Getz, N. Hacohen, Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48-61 (2015).
-
(2015)
Cell
, vol.160
, pp. 48-61
-
-
Rooney, M.S.1
Shukla, S.A.2
Wu, C.J.3
Getz, G.4
Hacohen, N.5
-
14
-
-
84958124766
-
Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy
-
C. Pfirschke, C. Engblom, S. Rickelt, V. Cortez-Retamozo, C. Garris, F. Pucci, T. Yamazaki, V. Poirier-Colame, A. Newton, Y. Redouane, Y.-J. Lin, G. Wojtkiewicz, Y. Iwamoto, M. Mino-Kenudson, T. G. Huynh, R. O. Hynes, G. J. Freeman, G. Kroemer, L. Zitvogel, R. Weissleder, M. J. Pittet, Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 44, 343-354 (2016).
-
(2016)
Immunity
, vol.44
, pp. 343-354
-
-
Pfirschke, C.1
Engblom, C.2
Rickelt, S.3
Cortez-Retamozo, V.4
Garris, C.5
Pucci, F.6
Yamazaki, T.7
Poirier-Colame, V.8
Newton, A.9
Redouane, Y.10
Lin, Y.-J.11
Wojtkiewicz, G.12
Iwamoto, Y.13
Mino-Kenudson, M.14
Huynh, T.G.15
Hynes, R.O.16
Freeman, G.J.17
Kroemer, G.18
Zitvogel, L.19
Weissleder, R.20
Pittet, M.J.21
more..
-
15
-
-
84962840922
-
Combination cancer therapies with immune checkpoint blockade: Convergence on interferon signaling
-
A. J. Minn, E. J. Wherry, Combination cancer therapies with immune checkpoint blockade: Convergence on interferon signaling. Cell 165, 272-275 (2016).
-
(2016)
Cell
, vol.165
, pp. 272-275
-
-
Minn, A.J.1
Wherry, E.J.2
-
16
-
-
84886698315
-
Innate and adaptive immune cells in the tumor microenvironment
-
T. F. Gajewski, H. Schreiber, Y.-X. Fu, Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014-1022 (2013).
-
(2013)
Nat. Immunol.
, vol.14
, pp. 1014-1022
-
-
Gajewski, T.F.1
Schreiber, H.2
Fu, Y.-X.3
-
17
-
-
84904406680
-
Tumor-associated macrophages: From mechanisms to therapy
-
R. Noy, J. W. Pollard, Tumor-associated macrophages: From mechanisms to therapy. Immunity 41, 49-61 (2014).
-
(2014)
Immunity
, vol.41
, pp. 49-61
-
-
Noy, R.1
Pollard, J.W.2
-
19
-
-
58149314579
-
NFATc1 regulates PD-1 expression upon T cell activation
-
K. J. Oestreich, H. Yoon, R. Ahmed, J. M. Boss, NFATc1 regulates PD-1 expression upon T cell activation. J. Immunol. 181, 4832-4839 (2008).
-
(2008)
J. Immunol.
, vol.181
, pp. 4832-4839
-
-
Oestreich, K.J.1
Yoon, H.2
Ahmed, R.3
Boss, J.M.4
-
20
-
-
59649095271
-
DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors
-
S. Gilfillan, C. J. Chan, M. Cella, N. M. Haynes, A. S. Rapaport, K. S. Boles, D. M. Andrews, M. J. Smyth, M. Colonna, DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J. Exp. Med. 205, 2965-2973 (2008).
-
(2008)
J. Exp. Med.
, vol.205
, pp. 2965-2973
-
-
Gilfillan, S.1
Chan, C.J.2
Cella, M.3
Haynes, N.M.4
Rapaport, A.S.5
Boles, K.S.6
Andrews, D.M.7
Smyth, M.J.8
Colonna, M.9
-
21
-
-
33745978399
-
Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation
-
T. R. Mempel, M. J. Pittet, K. Khazaie, W. Weninger, R. Weissleder, H. von Boehmer, U. H. von Andrian, Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity 25, 129-141 (2006).
-
(2006)
Immunity
, vol.25
, pp. 129-141
-
-
Mempel, T.R.1
Pittet, M.J.2
Khazaie, K.3
Weninger, W.4
Weissleder, R.5
Von Boehmer, H.6
Von Andrian, U.H.7
-
22
-
-
84924363038
-
A novel model for IFN-g-mediated autoinflammatory syndromes
-
R. L. Reinhardt, H.-E. Liang, K. Bao, A. E. Price, M. Mohrs, B. L. Kelly, R. M. Locksley, A novel model for IFN-g-mediated autoinflammatory syndromes. J. Immunol. 194, 2358-2368 (2015).
-
(2015)
J. Immunol.
, vol.194
, pp. 2358-2368
-
-
Reinhardt, R.L.1
Liang, H.-E.2
Bao, K.3
Price, A.E.4
Mohrs, M.5
Kelly, B.L.6
Locksley, R.M.7
-
24
-
-
28544449847
-
Divergent immunoglobulin g subclass activity through selective Fc receptor binding
-
F. Nimmerjahn, J. V. Ravetch, Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310, 1510-1512 (2005).
-
(2005)
Science
, vol.310
, pp. 1510-1512
-
-
Nimmerjahn, F.1
Ravetch, J.V.2
-
25
-
-
84942306499
-
FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis
-
R. Dahan, E. Sega, J. Engelhardt, M. Selby, A. J. Korman, J. V. Ravetch, FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell 28, 285-295 (2015).
-
(2015)
Cancer Cell
, vol.28
, pp. 285-295
-
-
Dahan, R.1
Sega, E.2
Engelhardt, J.3
Selby, M.4
Korman, A.J.5
Ravetch, J.V.6
-
26
-
-
32044464340
-
The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes
-
P. V. Beum, A. D. Kennedy, M. E. Williams, M. A. Lindorfer, R. P. Taylor, The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J. Immunol. 176, 2600-2609 (2006).
-
(2006)
J. Immunol.
, vol.176
, pp. 2600-2609
-
-
Beum, P.V.1
Kennedy, A.D.2
Williams, M.E.3
Lindorfer, M.A.4
Taylor, R.P.5
-
27
-
-
67651149465
-
Structure of the murine unglycosylated IgG1 Fc fragment
-
M. J. Feige, S. Nath, S. R. Catharino, D. Weinfurtner, Structure of the murine unglycosylated IgG1 Fc fragment. J. Mol. Biol. 391, 599-608 (2009).
-
(2009)
J. Mol. Biol.
, vol.391
, pp. 599-608
-
-
Feige, M.J.1
Nath, S.2
Catharino, S.R.3
Weinfurtner, D.4
-
28
-
-
84921745242
-
Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: Historical precedence and recent developments
-
R. P. Taylor, M. A. Lindorfer, Fcγ-receptor-mediated trogocytosis impacts mAb-based therapies: Historical precedence and recent developments. Blood 125, 762-766 (2015).
-
(2015)
Blood
, vol.125
, pp. 762-766
-
-
Taylor, R.P.1
Lindorfer, M.A.2
-
29
-
-
65549114676
-
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
-
P. Bruhns, B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez, S. Jorieux, M. Daeron, Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses. Blood 113, 3716-3725 (2009).
-
(2009)
Blood
, vol.113
, pp. 3716-3725
-
-
Bruhns, P.1
Iannascoli, B.2
England, P.3
Mancardi, D.A.4
Fernandez, N.5
Jorieux, S.6
Daeron, M.7
-
30
-
-
84875998684
-
Impact of immune complex size and glycosylation on IgG binding to human FcγRs
-
A. Lux, X. Yu, C. N. Scanlan, F. Nimmerjahn, Impact of immune complex size and glycosylation on IgG binding to human FcγRs. J. Immunol. 190, 4315-4323 (2013).
-
(2013)
J. Immunol.
, vol.190
, pp. 4315-4323
-
-
Lux, A.1
Yu, X.2
Scanlan, C.N.3
Nimmerjahn, F.4
-
31
-
-
84920031180
-
In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol
-
C. Wang, K. B. Thudium, M. Han, X.-T. Wang, H. Huang, D. Feingersh, C. Garcia, Y. Wu, M. Kuhne, M. Srinivasan, S. Singh, S. Wong, N. Garner, H. Leblanc, R. T. Bunch, D. Blanset, M. J. Selby, A. J. Korman, In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol. Res. 2, 846-856 (2014).
-
(2014)
Res.
, vol.2
, pp. 846-856
-
-
Wang, C.1
Thudium, K.B.2
Han, M.3
Wang, X.-T.4
Huang, H.5
Feingersh, D.6
Garcia, C.7
Wu, Y.8
Kuhne, M.9
Srinivasan, M.10
Singh, S.11
Wong, S.12
Garner, N.13
Leblanc, H.14
Bunch, R.T.15
Blanset, D.16
Selby, M.J.17
Korman, A.J.18
-
32
-
-
33748416499
-
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412
-
G. Suntharalingam, M. R. Perry, S. Ward, S. J. Brett, A. Castello-Cortes, M. D. Brunner, N. Panoskaltsis, Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).
-
(2006)
N. Engl. J. Med.
, vol.355
, pp. 1018-1028
-
-
Suntharalingam, G.1
Perry, M.R.2
Ward, S.3
Brett, S.J.4
Castello-Cortes, A.5
Brunner, M.D.6
Panoskaltsis, N.7
-
33
-
-
84920569758
-
Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412
-
K. Hussain, C. E. Hargreaves, A. Roghanian, R. J. Oldham, H. T. C. Chan, C. I. Mockridge, F. Chowdhury, B. Frendeus, K. S. Harper, J. C. Strefford, M. S. Cragg, M. J. Glennie, A. P. Williams, R. R. French, Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412. Blood 125, 102-110 (2015).
-
(2015)
Blood
, vol.125
, pp. 102-110
-
-
Hussain, K.1
Hargreaves, C.E.2
Roghanian, A.3
Oldham, R.J.4
Chan, H.T.C.5
Mockridge, C.I.6
Chowdhury, F.7
Frendeus, B.8
Harper, K.S.9
Strefford, J.C.10
Cragg, M.S.11
Glennie, M.J.12
Williams, A.P.13
French, R.R.14
-
34
-
-
84894552888
-
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions
-
V. Goede, K. Fischer, R. Busch, A. Engelke, B. Eichhorst, C. M. Wendtner, T. Chagorova, J. de la Serna, M.-S. Dilhuydy, T. Illmer, S. Opat, C. J. Owen, O. Samoylova, K.-A. Kreuzer, S. Stilgenbauer, H. Döhner, A. W. Langerak, M. Ritgen, M. Kneba, E. Asikanius, K. Humphrey, M. Wenger, M. Hallek, Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370, 1101-1110 (2014).
-
(2014)
N. Engl. J. Med.
, vol.370
, pp. 1101-1110
-
-
Goede, V.1
Fischer, K.2
Busch, R.3
Engelke, A.4
Eichhorst, B.5
Wendtner, C.M.6
Chagorova, T.7
De La Serna, J.8
Dilhuydy, M.-S.9
Illmer, T.10
Opat, S.11
Owen, C.J.12
Samoylova, O.13
Kreuzer, K.-A.14
Stilgenbauer, S.15
Döhner, H.16
Langerak, A.W.17
Ritgen, M.18
Kneba, M.19
Asikanius, E.20
Humphrey, K.21
Wenger, M.22
Hallek, M.23
more..
-
35
-
-
84929021792
-
FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic disease
-
F. Sclafani, D. Gonzalez de Castro, D. Cunningham, S. Hulkki Wilson, C. Peckitt, J. Capdevila, B. Glimelius, S. Roselló Keränen, A. Wotherspoon, G. Brown, D. Tait, R. Begum, J. Thomas, J. Oates, I. Chau, FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic disease. Clin. Cancer Res. 20, 4511-4519 (2014).
-
(2014)
Clin. Cancer Res.
, vol.20
, pp. 4511-4519
-
-
Sclafani, F.1
Gonzalez De Castro, D.2
Cunningham, D.3
Hulkki Wilson, S.4
Peckitt, C.5
Capdevila, J.6
Glimelius, B.7
Roselló Keränen, S.8
Wotherspoon, A.9
Brown, G.10
Tait, D.11
Begum, R.12
Thomas, J.13
Oates, J.14
Chau, I.15
-
36
-
-
0037306893
-
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
-
O. Manches, G. Lui, L. Chaperot, R. Gressin, J.-P. Molens, M.-C. Jacob, J.-J. Sotto, D. Leroux, J.-C. Bensa, J. Plumas, In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101, 949-954 (2003).
-
(2003)
Blood
, vol.101
, pp. 949-954
-
-
Manches, O.1
Lui, G.2
Chaperot, L.3
Gressin, R.4
Molens, J.-P.5
Jacob, M.-C.6
Sotto, J.-J.7
Leroux, D.8
Bensa, J.-C.9
Plumas, J.10
-
37
-
-
31444451572
-
Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism?
-
L. Arnould, M. Gelly, F. Penault-Llorca, L. Benoit, F. Bonnetain, C. Migeon, V. Cabaret, V. Fermeaux, P. Bertheau, J. Garnier, J.-F. Jeannin, B. Coudert, Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer 94, 259-267 (2006).
-
(2006)
Br. J. Cancer
, vol.94
, pp. 259-267
-
-
Arnould, L.1
Gelly, M.2
Penault-Llorca, F.3
Benoit, L.4
Bonnetain, F.5
Migeon, C.6
Cabaret, V.7
Fermeaux, V.8
Bertheau, P.9
Garnier, J.10
Jeannin, J.-F.11
Coudert, B.12
-
38
-
-
0034076307
-
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets
-
R. A. Clynes, T. L. Towers, L. G. Presta, J. V. Ravetch, Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6, 443-446 (2000).
-
(2000)
Nat. Med.
, vol.6
, pp. 443-446
-
-
Clynes, R.A.1
Towers, T.L.2
Presta, L.G.3
Ravetch, J.V.4
-
39
-
-
84945555686
-
Novel radiotracer for immunoPET imaging of PD-1 checkpoint expression on tumor infiltrating lymphocytes
-
A. Natarajan, A. T. Mayer, L. Xu, R. E. Reeves, J. Gano, S. S. Gambhir, Novel radiotracer for immunoPET imaging of PD-1 checkpoint expression on tumor infiltrating lymphocytes. Bioconjug. Chem. 26, 2062-2069 (2015).
-
(2015)
Bioconjug. Chem.
, vol.26
, pp. 2062-2069
-
-
Natarajan, A.1
Mayer, A.T.2
Xu, L.3
Reeves, R.E.4
Gano, J.5
Gambhir, S.S.6
-
40
-
-
84982098636
-
High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers
-
M. Hettich, F. Braun, M. D. Bartholomä, R. Schirmbeck, G. Niedermann, High-resolution PET imaging with therapeutic antibody-based PD-1/PD-L1 checkpoint tracers. Theranostics 6, 1629-1640 (2016).
-
(2016)
Theranostics
, vol.6
, pp. 1629-1640
-
-
Hettich, M.1
Braun, F.2
Bartholomä, M.D.3
Schirmbeck, R.4
Niedermann, G.5
-
41
-
-
84990942559
-
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
-
T. Schlothauer, S. Herter, C. F. Koller, S. Grau-Richards, V. Steinhart, C. Spick, M. Kubbies, C. Klein, P. Umaña, E. Mössner, Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng. Des. Sel. 29, 457-466 (2016).
-
(2016)
Protein Eng. Des. Sel.
, vol.29
, pp. 457-466
-
-
Schlothauer, T.1
Herter, S.2
Koller, C.F.3
Grau-Richards, S.4
Steinhart, V.5
Spick, C.6
Kubbies, M.7
Klein, C.8
Umaña, P.9
Mössner, E.10
-
42
-
-
85012158583
-
Primary, adaptive, and acquired resistance to cancer immunotherapy
-
P. Sharma, S. Hu-Lieskovan, J. A. Wargo, A. Ribas, Primary, adaptive, and acquired resistance to cancer immunotherapy. Cancer Cell 168, 707-723 (2017).
-
(2017)
Cancer Cell
, vol.168
, pp. 707-723
-
-
Sharma, P.1
Hu-Lieskovan, S.2
Wargo, J.A.3
Ribas, A.4
-
43
-
-
84961221351
-
Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma
-
W. Hugo, J. M. Zaretsky, L. Sun, C. Song, B. H. Moreno, S. Hu-Lieskovan, B. Berent-Maoz, J. Pang, B. Chmielowski, G. Cherry, E. Seja, S. Lomeli, X. Kong, M. C. Kelley, J. A. Sosman, D. B. Johnson, A. Ribas, R. S. Lo, Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35-44 (2016).
-
(2016)
Cell
, vol.165
, pp. 35-44
-
-
Hugo, W.1
Zaretsky, J.M.2
Sun, L.3
Song, C.4
Moreno, B.H.5
Hu-Lieskovan, S.6
Berent-Maoz, B.7
Pang, J.8
Chmielowski, B.9
Cherry, G.10
Seja, E.11
Lomeli, S.12
Kong, X.13
Kelley, M.C.14
Sosman, J.A.15
Johnson, D.B.16
Ribas, A.17
Lo, R.S.18
-
44
-
-
85019210402
-
Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response
-
B. Lehmann, M. Biburger, C. Brückner, A. Ipsen-Escobedo, S. Gordan, C. Lehmann, D. Voehringer, T. Winkler, N. Schaft, D. Dudziak, H. Sirbu, G. F. Weber, F. Nimmerjahn, Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response. Sci. Immunol. 2, eaah6413 (2017).
-
(2017)
Sci. Immunol.
, vol.2
, pp. eaah6413
-
-
Lehmann, B.1
Biburger, M.2
Brückner, C.3
Ipsen-Escobedo, A.4
Gordan, S.5
Lehmann, C.6
Voehringer, D.7
Winkler, T.8
Schaft, N.9
Dudziak, D.10
Sirbu, H.11
Weber, G.F.12
Nimmerjahn, F.13
-
45
-
-
84874598091
-
Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo
-
G. M. Thurber, K. S. Yang, T. Reiner, R. H. Kohler, P. Sorger, T. Mitchison, R. Weissleder, Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo. Nat. Commun. 4, 1504 (2013).
-
(2013)
Nat. Commun.
, vol.4
, pp. 1504
-
-
Thurber, G.M.1
Yang, K.S.2
Reiner, T.3
Kohler, R.H.4
Sorger, P.5
Mitchison, T.6
Weissleder, R.7
-
46
-
-
0030571019
-
A rapid high-resolution highperformance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles
-
G. R. Guile, P. M. Rudd, D. R. Wing, S. B. Prime, R. A. Dwek, A rapid high-resolution highperformance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal. Biochem. 240, 210-226 (1996).
-
(1996)
Anal. Biochem.
, vol.240
, pp. 210-226
-
-
Guile, G.R.1
Rudd, P.M.2
Wing, D.R.3
Prime, S.B.4
Dwek, R.A.5
-
47
-
-
0022532481
-
Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice
-
R. J. Kurlander, J. Hall, Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J. Clin. Invest. 77, 2010-2018 (1986).
-
(1986)
J. Clin. Invest.
, vol.77
, pp. 2010-2018
-
-
Kurlander, R.J.1
Hall, J.2
-
48
-
-
84929624401
-
Single cell resolution in vivo imaging of DNA damage following PARP inhibition
-
K. S. Yang, R. H. Kohler, M. Landon, R. Giedt, R. Weissleder, Single cell resolution in vivo imaging of DNA damage following PARP inhibition. Sci. Rep. 5, 10129 (2015).
-
(2015)
Sci. Rep.
, vol.5
, pp. 10129
-
-
Yang, K.S.1
Kohler, R.H.2
Landon, M.3
Giedt, R.4
Weissleder, R.5
-
49
-
-
80053080677
-
Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptorexpressing effector cells than direct internalization by the B cells
-
P. V. Beum, E. M. Peek, M. A. Lindorfer, F. J. Beurskens, P. J. Engelberts, P. W. H. I. Parren, J. G. J. van de Winkel, R. P. Taylor, Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptorexpressing effector cells than direct internalization by the B cells. J. Immunol. 187, 3438-3447 (2011).
-
(2011)
J. Immunol.
, vol.187
, pp. 3438-3447
-
-
Beum, P.V.1
Peek, E.M.2
Lindorfer, M.A.3
Beurskens, F.J.4
Engelberts, P.J.5
Parren, P.W.H.I.6
Van De Winkel, J.G.J.7
Taylor, R.P.8
-
50
-
-
84929373209
-
Imaging windows for long-term intravital imaging: General overview and technical insights
-
M. Alieva, L. Ritsma, R. J. Giedt, R. Weissleder, Imaging windows for long-term intravital imaging: General overview and technical insights. IntraVital 3, e29917 (2014).
-
(2014)
IntraVital
, vol.3
, pp. e29917
-
-
Alieva, M.1
Ritsma, L.2
Giedt, R.J.3
Weissleder, R.4
-
51
-
-
0347717903
-
T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases
-
T. R. Mempel, S. E. Henrickson, U. H. von Andrian, T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427, 154-159 (2004).
-
(2004)
Nature
, vol.427
, pp. 154-159
-
-
Mempel, T.R.1
Henrickson, S.E.2
Von Andrian, U.H.3
-
52
-
-
22544487815
-
FcγRIV: A novel FcR with distinct IgG subclass specificity
-
F. Nimmerjahn, P. Bruhns, K. Horiuchi, J. V. Ravetch, FcγRIV: A novel FcR with distinct IgG subclass specificity. Immunity 23, 41-51 (2005).
-
(2005)
Immunity
, vol.23
, pp. 41-51
-
-
Nimmerjahn, F.1
Bruhns, P.2
Horiuchi, K.3
Ravetch, J.V.4
|